Table 1 US FDA-approved CAR-T cell therapies
Generic name | Trade name | Target antigen | Indication | Date of FDA approval |
|---|---|---|---|---|
Axicabtagene ciloleucel | Yescarta® | CD19 | Large B cell lymphoma | October 2017 |
Follicular lymphoma | March 2021 | |||
Tisagenlecleucel | Kymriah® | CD19 | Acute lymphoblastic leukemia | August 2017 |
Large B cell lymphoma | May 2018 | |||
Brexucabtagene autoleucel | Tecartus® | CD19 | Mantle cell lymphoma | July 2020 |
Liscobtagene maraleucel | Breyanzi® | CD19 | Large B cell lymphoma | February 2021 |
Idecabtagene vicleucel | Abecma® | BCMA | Multiple myeloma | March 2021 |
Ciltacabtagene autoleucel | Carvykti® | BCMA | Multiple myeloma | February 2022 |